Patents Assigned to Biosynexus Incorporated
  • Antimicrobial polymer conjugates
    Publication number: 20070292404
    Abstract: The present invention relates to the conjugation of antimicrobial agents to water-soluble polymers to improve their clinical properties in terms of their pharmacokinetics, pharmacodynamics, and reduced immunogenicity. More specifically, the present invention relates to the conjugation of antimicrobial agents such as lysostaphin to poly(alkylene oxides), such as poly(ethylene glycol) (PEG).
    Type: Application
    Filed: March 27, 2007
    Publication date: December 20, 2007
    Applicant: Biosynexus Incorporated
    Inventors: Scott Walsh, Anjali Shah, James Mond, Andrew Lees, Joseph Drabick
  • Neutralization of bacterial spores
    Publication number: 20070238652
    Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., a lantibiotic-based spore decontaminant (e.g., comprising nisin)) and methods of neutralizing (e.g., killing or inhibiting growth or inhibiting germination of) bacteria (e.g., cells and spores). For example, the present invention provides nisin-based compounds (e.g., for bacterial spore decontamination) and methods of using the same in research, therapeutic and drug screening applications.
    Type: Application
    Filed: February 8, 2007
    Publication date: October 11, 2007
    Applicant: Biosynexus Incorporated
    Inventors: John Kokai-Kun, James Mond, Jonathan de la Harpe
  • Compositions and methods for treating bacteria
    Publication number: 20070185026
    Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.
    Type: Application
    Filed: October 11, 2006
    Publication date: August 9, 2007
    Applicant: Biosynexus Incorporated
    Inventors: Scott Walsh, Mary Pittaway, James Mond
  • Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
    Patent number: 7250494
    Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: July 31, 2007
    Assignee: Biosynexus Incorporated
    Inventors: Jeffrey R. Stinson, Richard F. Schuman, James J. Mond, Andrew Lees, Gerald Walter Fischer
  • Compositions and methods for treating bacteria
    Publication number: 20070060506
    Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.
    Type: Application
    Filed: July 28, 2006
    Publication date: March 15, 2007
    Applicant: Biosynexus Incorporated
    Inventors: Scott Walsh, Mary Pittaway, James Mond
  • Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
    Patent number: 7169903
    Abstract: The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: January 30, 2007
    Assignee: Biosynexus Incorporated
    Inventors: Richard F. Schuman, John Fitzgerald Kokai-Kun, Simon J. Foster, Jeffrey R. Stinson, Gerald Walter Fischer
  • Topical anti-infective formulations
    Publication number: 20040192581
    Abstract: Topical compositions containing an effective amount of lysostaphin and/or one or more lantibiotics in a pharmaceutically acceptable carrier for topical application. Methods for treating skin or wound infections, including, but not limited to infected abrasions, skin or surface cuts, burns or surgical incisions or decubiti, with the topical compositions are also disclosed.
    Type: Application
    Filed: December 10, 2003
    Publication date: September 30, 2004
    Applicant: Biosynexus Incorporated
    Inventors: Scott M. Walsh, Anjali G. Shah, James J. Mond